Platelet dose for prophylactic platelet transfusions

References

• Heal JM, Blumberg N. Optimizing platelet transfusion therapy. Blood Rev.18, 149–165 (2004).
   PubMed Web of Science ®Google Scholar
• Guidelines for the use of platelet transfusions. Br. J. Haematol.122, 10–23 (2003).
   PubMed Web of Science ®Google Scholar
• Tinmouth AT, Freedman J. Prophylactic platelet transfusions: which dose is the best dose? A review of the literature. Transfus. Med. Rev.17, 181–193 (2003).
   PubMedGoogle Scholar
• Heddle NM, Cook RJ, Tinmouth A et al. A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood113, 1564–1573 (2009).
   PubMed Web of Science ®Google Scholar
• Slichter SJ, Kaufman RM, Assmann SF et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N. Engl. J. Med.362, 600–613 (2010).
   PubMed Web of Science ®Google Scholar
• Stanworth SJ, Dyer C, Casbard A, Murphy MF. Feasibility and usefulness of self-assessment of bleeding in patients with haematological malignancies, and the association between platelet count and bleeding. Vox Sang.91, 63–69 (2006).
   PubMed Web of Science ®Google Scholar
• van Rhenen D, Gulliksson H, Cazenave JP et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood101, 2426–2433 (2003).
   PubMed Web of Science ®Google Scholar
• McCullough J, Vesole DH, Benjamin RJ et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood104, 1534–1541 (2004).
   PubMed Web of Science ®Google Scholar
• Cook RJ, Heddle NM, Rebulla P, Sigouin CS, Webert KE. Methods for the analysis of bleeding outcomes in randomized trials of PLT transfusion triggers. Transfusion44, 1135–1142 (2004).
   PubMedGoogle Scholar
• Klumpp TR, Herman JH, Gaughan JP et al. Clinical consequences of alterations in platelet transfusion dose: a prospective, randomized, double-blind trial. Transfusion39, 674–681 (1999).
   PubMed Web of Science ®Google Scholar
• Norol F, Bierling P, Roudot-Thoraval F et al. Platelet transfusion: a dose–response study. Blood92, 1448–1453 (1998).
   PubMed Web of Science ®Google Scholar
• Roy AJ, Jaffe N, Djerassi I. Prophylactic platelet transfusions in children with acute leukemia: a dose response study. Transfusion13, 283–290 (1973).
   PubMed Web of Science ®Google Scholar
• Goodnough LT, Kuter DJ, McCullough J et al. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. Blood98, 1346–1351 (2001).
   PubMed Web of Science ®Google Scholar
• Tinmouth A, Tannock IF, Crump M et al. Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design. Transfusion44, 1711–1719 (2004).
   PubMed Web of Science ®Google Scholar
• Sensebe L, Giraudeau B, Bardiaux L et al. The efficiency of transfusing high doses of platelets in hematologic patients with thrombocytopenia: results of a prospective, randomized, open, blinded end point (PROBE) study. Blood105, 862–864 (2005).
   PubMed Web of Science ®Google Scholar
• Cid J, Lozano M. Lower or higher doses for prophylactic platelet transfusions: results of a meta-analysis of randomized controlled trials. Transfusion47, 464–470 (2007).
   PubMedGoogle Scholar
• Konkle BA, Nemo GJ. Defining effective therapies in transfusion medicine and hemostasis: new opportunities with the TMH Network. Transfusion45, 1404–1406 (2005).
   PubMedGoogle Scholar
• Slichter SJ. Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients. J. Clin. Apher.21, 78–84 (2006).
   PubMedGoogle Scholar
• Cid J, Lozano M, Escolar G. ABO compatibility in platelet transfusion. N. Engl. J. Med.362, 2140 (2010).
   PubMedGoogle Scholar
• Lozano M, Cid J. The clinical implications of platelet transfusions associated with ABO or Rh(D) incompatibility. Transfus. Med. Rev.17, 57–68 (2003).
   PubMed Web of Science ®Google Scholar
• Heal JM, Masel D, Rowe JM, Blumberg N. Circulating immune complexes involving the ABO system after platelet transfusion. Br. J. Haematol.85, 566–572 (1993).
   PubMedGoogle Scholar
• Slichter SJ, Davis K, Enright H et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood105, 4106–4114 (2005).
   PubMed Web of Science ®Google Scholar
• Lozano M, Heddle NM, Williamson LM, Wang G, AuBuchon JP, Dumont LJ. Practices associated with ABO-incompatible platelet transfusions: a BEST collaborative international survey. Transfusion (2010) (In press).
   Google Scholar
• Heddle NM, Cook RJ, Webert KE, Sigouin C, Rebulla P. Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion43, 742–752 (2003).
   PubMed Web of Science ®Google Scholar
• Wandt H, Schaefer-Eckart K, Frank M, Birkmann J, Wilhelm M. A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant.37, 387–392 (2006).
   PubMed Web of Science ®Google Scholar
• Avvisati G, ten Cate JW, Buller HR, Mandelli F. Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet2, 122–124 (1989).
   PubMed Web of Science ®Google Scholar
• Ben-Bassat I, Douer D, Ramot B. Tranexamic acid therapy in acute myeloid leukemia: possible reduction of platelet transfusions. Eur. J. Haematol.45, 86–89 (1990).
   PubMed Web of Science ®Google Scholar
• Shpilberg O, Blumenthal R, Sofer O et al. A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. Leuk. Lymph.19, 141–144 (1995).
   PubMed Web of Science ®Google Scholar
• Fricke W, Alling D, Kimball J, Griffith P, Klein H. Lack of efficacy of tranexamic acid in thrombocytopenic bleeding. Transfusion31, 345–348 (1991).
   PubMed Web of Science ®Google Scholar